SAB Biotherapeutics Analyst Ratings
SAB Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 8.32% | HC Wainwright & Co. | $2 → $1 | Maintains | Buy |
| 10/05/2023 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 08/21/2023 | 116.64% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 06/21/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/16/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 06/15/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | Buy → Buy |
| 05/17/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | Buy → Buy |
| 04/27/2023 | 224.96% | Chardan Capital | → $3 | Reiterates | → Buy |
| 04/13/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 04/03/2023 | 333.28% | HC Wainwright & Co. | → $4 | Reiterates | → Buy |
| 11/29/2022 | 333.28% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 08/11/2022 | 224.96% | Chardan Capital | $7 → $3 | Maintains | Buy |
| 05/13/2022 | 658.23% | Chardan Capital | $10 → $7 | Maintains | Buy |
| 04/01/2022 | 983.19% | Chardan Capital | $17 → $10 | Maintains | Buy |
| 11/05/2021 | 1741.42% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/02/2021 | 2391.33% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 8.32% | HC Wainwright & Co. | $2 → $1 | 維護 | 買 |
| 10/05/2023 | — | 拉登堡塔爾曼 | 降級 | 買入 → 中性 | |
| 08/21/2023 | 116.64% | HC Wainwright & Co. | 4 美元 → 2 美元 | 維護 | 買 |
| 06/21/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 購買 → 購買 |
| 06/16/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 購買 → 購買 |
| 06/15/2023 | 224.96% | 查丹資本 | → 3 美元 | 重申 | 購買 → 購買 |
| 05/17/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | 購買 → 購買 |
| 04/27/2023 | 224.96% | 查丹資本 | → 3 美元 | 重申 | → 購買 |
| 04/13/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | → 購買 |
| 04/03/2023 | 333.28% | HC Wainwright & Co. | → 4 美元 | 重申 | → 購買 |
| 2022 年 11 月 29 日 | 333.28% | HC Wainwright & Co. | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/11/2022 | 224.96% | 查丹資本 | 7 美元 → 3 美元 | 維護 | 買 |
| 05/13/2022 | 658.23% | 查丹資本 | 10 美元 → 7 美元 | 維護 | 買 |
| 04/01/2022 | 983.19% | 查丹資本 | 17 美元 → 10 美元 | 維護 | 買 |
| 2021 年 5 月 11 日 | 1741.42% | 查丹資本 | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/02/2021 | 2391.33% | 貝爾德 | → 23 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的目標價格是多少？
The latest price target for SAB Biotherapeutics (NASDAQ: SABS) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $1.00 expecting SABS to rise to within 12 months (a possible 8.32% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月14日公佈了SAB Biotherapeutics（納斯達克股票代碼：SABS）的最新目標股價。該分析公司將目標股價定爲1.00美元，預計SABS將在12個月內升至12個月內（可能上漲8.32％）。去年有11家分析公司公佈了評級。
What is the most recent analyst rating for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的最新分析師評級是多少？
The latest analyst rating for SAB Biotherapeutics (NASDAQ: SABS) was provided by HC Wainwright & Co., and SAB Biotherapeutics maintained their buy rating.
HC Wainwright & Co. 提供了SAB Biotherapeutics（納斯達克股票代碼：SABS）的最新分析師評級，SAB Biotherapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for SAB Biotherapeutics (SABS)?
SAB Biotherapeutics（SABS）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與SAB Biotherapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。SAB Biotherapeutics的最新評級是在2023年11月14日發佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating SAB Biotherapeutics (SABS) correct?
分析師對SAB Biotherapeutics（SABS）的評級是否正確？
While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $2.00 to $1.00. The current price SAB Biotherapeutics (SABS) is trading at is $0.92, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的SAB Biotherapeutics（SABS）評級維持不變，目標股價爲2.00美元至1.00美元。SAB Biotherapeutics（SABS）目前的交易價格爲0.92美元，超出了分析師的預期區間。